The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Open accessAbstract
BACKGROUND: TP53 mutation is the most common mutation in hepatocellular carcinoma (HCC), and it affects the progression and prognosis of HCC. We investigated how TP53 mutation regulates the HCC immunophenotype and thus affects the prognosis of HCC. METHODS: HCC samples. Then, the influence of the IPM on the immune microenvironment in HCC was comprehensively analysed. FINDINGS: TP53 mutation resulted in the downregulation of the immune response in HCC. Thirty-seven of the 312 immune response-related genes were differentially expressed based on TP53 mutation status. An IPM was established and validated based on 865 patients with HCC to differentiate patients with a low or high risk of poor survival. A nomogram was also established for clinical application. Functional enrichment analysis showed that the humoral immune response and immune system diseases pathway represented the major function and pathway, respectively, related to the IPM genes. Moreover, we found that the patients in the high-risk group had higher fractions of T cells follicular helper, T cells regulatory (Tregs) and macrophages M0 and presented higher expression of CTLA-4, PD-1 and TIM-3 than the low-risk group. INTERPRETATION: TP53 mutation is strongly related to the immune microenvironment in HCC. Our IPM, which is sensitive to TP53 mutation status, may have important implications for identifying subgroups of HCC patients with low or high risk of unfavourable survival. FUND: This work was supported by the International Science and Technology Cooperation Projects (2016YFE0107100), the Capital Special Research Project for Health Development (2014-2-4012), the Beijing Natural Science Foundation (L172055 and 7192158), the National Ten Thousand Talent Program, the Fundamental Research Funds for the Central Universities (3332018032), and the CAMS Innovation Fund for Medical Science (CIFMS) (2017-I2M-4-003 and 2018-I2M-3-001).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“During cancer development in immune-competent hosts, to evade antitumour immune responses, less immunogenic cancer cells are selected (immune selection) and immunosuppressive networks are established (immune escape) according to the cancer immunoediting hypothesis [52,53].”
BackgroundA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases
Xie, C., Mao, X., Huang, J., Ding, Y., Wu, J., Dong, S., Kong, L., Gao, G., Li, C.-Y., & Wei, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr483 · Cited by 5,094
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Regression Shrinkage and Selection via The Lasso: A Retrospective
Tibshirani, R. (2011) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2011.00771.x · Cited by 3,589
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Xu, R.-H., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K., Yi, S., Shi, W., Quan, Q., Li, K., et al. (2017) · Nature Materials · doi:10.1038/nmat4997 · Cited by 862
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 693
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Gui, J., & Li, H. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti422 · Cited by 551
ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer
Jiang, Y., Zhang, Q., Hu, Y., Li, T., Yu, J., Zhao, L., Ye, G., Deng, H., Mou, T., Cai, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002116 · Cited by 458
Self-citationBulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H., Mancham, S., Pedroza-Gonzalez, A., Polak, W. G., de Jonge, J., Gaspersz, M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412
Biton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 351
Development and validation of an immune gene-set based Prognostic signature in ovarian cancer
Shen, S., Wang, G., Zhang, R., Zhao, Y., Yu, H., Wei, Y., & Chen, F. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.054 · Cited by 257
NK cells regulating T cell responses: mechanisms and outcome
Crouse, J., Xu, H. C., Lang, P. A., & Oxenius, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.11.001 · Cited by 242
Wu, J., Li, J., Salcedo, R., Mivechi, N. F., Trinchieri, G., & Horuzsko, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0938 · Cited by 238
Erdal, E., Haider, S., Rehwinkel, J., Harris, A. L., & McHugh, P. J. (2017) · Genes & Development · doi:10.1101/gad.289769.116 · Cited by 227
CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy
Rosenberg, J., & Huang, J. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.11.006 · Cited by 175
Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer
Rao, C. V., Asch, A. S., & Yamada, H. Y. (2017) · Carcinogenesis · doi:10.1093/carcin/bgw118 · Cited by 161
Neskey, D. M., Osman, A. A., Ow, T. J., Katsonis, P., McDonald, T., Hicks, S. C., Hsu, T.-K., Pickering, C. R., Ward, A., Patel, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2735 · Cited by 158
On the use of Harrell’s C for clinical risk prediction via random survival forests
Schmid, M. C., Wright, M. N., & Ziegler, A. (2016) · Expert Systems with Applications · doi:10.1016/j.eswa.2016.07.018 · Cited by 155
TREM-1 Expression in Tumor-associated Macrophages and Clinical Outcome in Lung Cancer
Ho, C., Liao, W., Wang, C.-Y., Lu, Y.-H., Huang, H., Chen, H., Chan, W., Chen, H., & Yang, P. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200704-641oc · Cited by 154
Yuan, R., Jeng, Y., Chen, H., Lai, P., Pan, H., Fj, H., Lin, C., Lee, P., & Hsu, H. (2006) · The Journal of Pathology · doi:10.1002/path.2011 · Cited by 146
Liu, J., Ma, Q., Zhang, M., Wang, X., Zhang, D., Li, W., Wang, F., & Wu, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.001 · Cited by 130
Progress in non-invasive detection of liver fibrosis
Chengxi, L., Li, R., & Zhang, W. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0018 · Cited by 123
Li, Y., Lu, Z., Che, Y., Wang, J., Sun, S., Huang, J., Mao, S., Lei, Y., Chen, Z., & He, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356147 · Cited by 122
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 121
Self-citationClinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
Dowell, S. P., Wilson, P., Derias, N. W., Lane, D. P., & Hall, P. A. (1994) · PubMed · Cited by 110
Huang, Y. L., Wang, F., Wang, T., Wang, Y., Zhu, Z., Gao, Y., & Zhi, D. (2012) · Digestion · doi:10.1159/000342801 · Cited by 106
Tanaka, S., Arii, S., Yasen, M., Mogushi, K., Su, N., Zhao, C. N., Imoto, I., Eishi, Y., Inazawa, J., Miki, Y., et al. (2008) · British journal of surgery · doi:10.1002/bjs.6011 · Cited by 101
A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs
Kiran, M., Chatrath, A., Tang, X., Keenan, D. M., & Dutta, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1416-y · Cited by 100
Lai, P. B. S., Chi, T., & Chen, G. G. (2006) · APOPTOSIS · doi:10.1007/s10495-006-0571-1 · Cited by 89
Inada, Y., Mizukoshi, E., Seike, T., Tamai, T., Iida, N., Kitahara, M., Yamashita, T., Arai, K., Terashima, T., Fushimi, K., et al. (2018) · Hepatology · doi:10.1002/hep.30212 · Cited by 71
Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation
Manning, A. L., Benes, C. H., & Dyson, N. J. (2013) · Oncogene · doi:10.1038/onc.2013.201 · Cited by 54
Yang, Y., Lü, Q., Shao, X., Mo, B., Nie, X., Liu, W., Chen, X., Tang, Y., Deng, Y., & Yan, J. (2018) · Journal of Cancer · doi:10.7150/jca.23762 · Cited by 52
Huang, Y. L., Wang, F., Wang, Y., Zhu, Z., Gao, Y., Ma, Z., Xu, R., & Zhi, D. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12418 · Cited by 45
Skoulidis, F., Hellmann, M. D., Awad, M. M., Rizvi, H. A., Carter, B. W., Denning, W. L., Elamin, Y. Y., Zhang, J. J., Leonardi, G. C., Halpenny, D. F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9016 · Cited by 26
Cited by
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Yang, C., Huang, X., Li, Y., Chen, J., Lv, Y., & Dai, S. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa164 · Cited by 269
Immunotherapy for hepatocellular carcinoma
Zongyi, Y., & Xiaowu, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 265
CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01777-4 · Cited by 6
“All included studies have received approval from their respective ethical review committees.”
Background
Metadata
- Authors
- Long, J., Wang, A., Bai, Y., Lin, J., Yang, X., Wang, D., Yang, X., Jiang, Y., & Zhao, H.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 42
- Pages
- 363-374
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2922356294
- Cited by
- 380
- References
- 59
- FWCI
- 28.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.